publicações selecionadas
-
artigo académico
- Development and Application of a Novel Multi-Channel In Vitro Electrical Stimulator for Cellular Research. BMC Biomedical Engineering. 2025
- Baclofen modulates the immune response after spinal cord injury with locomotor benefits. British Journal of Pharmacology. 2025
- Baclofen modulates the immune response after spinal cord injury with locomotor benefits. British Journal of Pharmacology. 2024
- A multi-channel in vitro electrical stimulator for neuroscience 2024
- Abstract. European Journal of Clinical Investigation. 2023
- Befiradol treatment ameliorated the motor dysfunction of Spinocerebellar Ataxia Type 3 mouse model. Neuroscience Applied. 2022
-
documento
- ACTIVATED MACROPHAGES AND SPINAL CORD INJURY REPAIR: THE SECRETOME EFFECT 2025
- Therapeutic efficacy of chronic 5-HT1A receptor agonism by befiradol in Spinocerebellar Ataxia Type 3 mice 2024
- ACTIVATED MACROPHAGES AND SPINAL CORD INJURY REPAIR: THE SECRETOME EFFECT 2024
- Combined admnistration of Baclofen with Pregabalin as a potential therapy for spinal cord injury 2023
- Motor coordination and balance ameliorated after treatment of the CMVMJD135 mouse model of Spinocerebellar Ataxia Type 3 with befiradol 2022
- Preclinical study of a 5-HT1A receptor specific agonist in the CMVMJD135 mouse model of Machado-Joseph disease. 2022
- Pre and post-symptomatic treatment with NLX-112 improved the balance and motor coordination of the CMVMJD135 mouse model of Machado-Joseph Disease 2022
- Preclinical study of a 5-HT1A receptor specific agonist in the CMVMJD135 mouse model of Machado-Joseph disease 2022
- Can chronic activation of serotonergic signalling be a therapeutic approach for neurodegenerative diseases? 2021
- Can chronic activation of serotonergic signalling be atherapeutic approach for neurodegenerative diseases? 2021
- NLX-112 improved the motor coordination and balance in a Mouse Experimental Model of Machado-Joseph Disease 2021
- Does activation of serotonergic treatment suppress proteotoxicity in mouse models of neurodegenerative diseases? 2021
- Serotonergic Signalling Activation as a Therapeutic Approach for Neurodegenerative Disorders 2021
- Serotonergic Signalling Activation as a Therapeutic Approach for Neurodegenerative Diseases 2021
- Serotonergic Signalling Activation as a Therapeutic Approach for Neurodegenerative Diseases 2020
- The 5-HT 1A receptor agonist NLX-112 rescues motor swimming deficits in Spinocerebellar Ataxia type 3 mice